We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD)

This study has been withdrawn prior to enrollment.
(Resources needed to complete the study were not able to be obtained.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01569373
First Posted: April 3, 2012
Last Update Posted: October 19, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Mark R. Litzow, Mayo Clinic
  Purpose
Samples of blood and urine will be analyzed for biomarkers to check their predictivity of Graft-versus-Host Disease (GVHD) outcomes.

Condition
Blood Stem Cell Transplant Failure

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD).

Resource links provided by NLM:


Further study details as provided by Mark R. Litzow, Mayo Clinic:

Primary Outcome Measures:
  • Diagnosis of severe acute GVHD [ Time Frame: 2 months ]

Enrollment: 0
Study Start Date: March 2012
Estimated Study Completion Date: October 2017
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts
Post allogeneic SCT patients
Patients who have undergone an allogeneic stem cell transplant.

Detailed Description:
To determine if serum biomarkers of inflammation correlate with onset and severity of acute GVHD, particularly GVHD of the gut.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who have undergone an allogeneic stem cell transplant being followed for post transplant care.
Criteria

Inclusion Criteria:

  • 18 years old or older patients
  • Undergoing allogeneic stem cell transplant

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01569373


Locations
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: Mark Litzow, MD Mayo Clinic
  More Information

Responsible Party: Mark R. Litzow, MD, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01569373     History of Changes
Other Study ID Numbers: 12-001493
First Submitted: March 29, 2012
First Posted: April 3, 2012
Last Update Posted: October 19, 2017
Last Verified: October 2017

Keywords provided by Mark R. Litzow, Mayo Clinic:
Allogeneic stem cell transplant
Graft versus Host Disease
GVHD

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases